JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Ultragenyx Pharmaceutical Inc

Fermé

SecteurSoins de santé

33.6 -0.3

Résumé

Variation du prix de l'action

24h

Actuel

Min

33.42

Max

33.62

Chiffres clés

By Trading Economics

Revenu

36M

-115M

Ventes

27M

166M

Marge bénéficiaire

-69.041

Employés

1,294

EBITDA

35M

-91M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+172.89% upside

Dividendes

By Dow Jones

Prochains Résultats

4 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

625M

3.3B

Ouverture précédente

33.9

Clôture précédente

33.6

Sentiment de l'Actualité

By Acuity

100%

0%

350 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Ultragenyx Pharmaceutical Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 oct. 2025, 18:41 UTC

Résultats

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 oct. 2025, 18:31 UTC

Résultats

Correction to Procter & Gamble to Focus on Innovation

24 oct. 2025, 16:25 UTC

Principaux Mouvements du Marché

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 oct. 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 oct. 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct. 2025, 21:07 UTC

Résultats

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct. 2025, 20:58 UTC

Résultats

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 oct. 2025, 20:40 UTC

Résultats

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct. 2025, 20:24 UTC

Résultats

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:23 UTC

Résultats

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:13 UTC

Résultats

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct. 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct. 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct. 2025, 19:33 UTC

Résultats

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 oct. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 oct. 2025, 18:52 UTC

Résultats

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct. 2025, 18:41 UTC

Résultats

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct. 2025, 18:03 UTC

Résultats

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 oct. 2025, 18:02 UTC

Résultats

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 oct. 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 oct. 2025, 16:57 UTC

Résultats

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 oct. 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 oct. 2025, 16:44 UTC

Market Talk
Résultats

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 oct. 2025, 16:39 UTC

Market Talk
Résultats

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 oct. 2025, 16:33 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 16:23 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24 oct. 2025, 16:07 UTC

Résultats

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparaison

Variation de prix

Ultragenyx Pharmaceutical Inc prévision

Objectif de Prix

By TipRanks

172.89% hausse

Prévisions sur 12 Mois

Moyen 91.5 USD  172.89%

Haut 128 USD

Bas 65 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

13 ratings

13

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

32.76 / 39.24Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

350 / 371Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
help-icon Live chat